2025, Number 4
Kidney transplant with hepatitis core positive living donor: case report
Language: Spanish
References: 13
Page: 195-200
PDF size: 249.37 Kb.
ABSTRACT
Introduction: Renal transplantation stands as the primary treatment for end-stage renal disease. Renal transplant guidelines in Peru advise against utilizing donors with positive hepatitis core, excluding them as potential donors. Nevertheless, current studies suggest that the risk of complications in these donors is minimal, and with the appropriate protocol, it does not pose a significant risk to the recipient. Case Report: This presents the first case of renal transplant conducted in Huancayo City from a hepatitis core-positive donor, with the recipient showing favorable evolution during the 6-month follow-up. Discussion: Renal transplantation from donors with positive hepatitis B core is not considered a contraindication, as multiple studies have shown low mortality rates and a positive prognosis. Conclusion: Donors with hepatitis core positivity represent an excellent choice for renal donation, and with the appropriate protocol, they should be considered as candidates for donation.REFERENCES
Hospital Cayetano Heredia. Guía de práctica clínicade manejo de trasplante renal adulto [Internet]. Lima(PE): Hospital Cayetano Heredia; 2021 [citado 8 oct2025]. Resolución Directoral N°439-2021-HCH/06.Disponible en: https://www.hospitalcayetano.gob.pe/PortalWeb/wp-content/uploads/resoluciones/2021/RD/RD_439-2021-HCH-DG.pdf.
Jones JM, Kracalik I, Levi ME, Bowman JS, BergerJJ, Bixler D, et al. Assessing Solid Organ Donors andMonitoring Transplant Recipients for HumanImmunodeficiency Virus, Hepatitis B Virus, andHepatitis C Virus Infection — U.S. Public HealthService Guideline, 2020. MMWR Recomm Rep. 26de junio de 2020;69(4):1-16. doi: 10.15585/mmwr.rr6904a1.
Wang X ding, Liu J peng, Song T run, Huang Z li,Fan Y, Shi Y ying, et al. Kidney Transplantation fromHepatitis B Surface Antigen (HBsAg)–PositiveLiving Donors to HBsAg-Negative Recipients:Clinical Outcomes at a High-Volume Center inChina. Clin Infect Dis. 15 de marzo de2021;72(6):1016-23. doi: 10.1093/cid/ciaa178.